Bringing a new therapy to market is a long and complex process. Most biotechnology and pharmaceutical companies do not have the infrastructure, resources, or expertise to manage every stage in-house.

This is where a CDMO (Contract Development and Manufacturing Organization) becomes essential. A CDMO combines development expertise with manufacturing capabilities, enabling companies to accelerate timelines, scale reliably, and maintain compliance with global regulatory standards.

Selecting the right partner can directly impact both speed-to-market and long-term commercial success, particularly for peptide and oligo programs. A CDMO addresses this by providing support across the drug development lifecycle. Unlike a CMO (Contract Manufacturing Organization) that focuses exclusively on production, a CDMO also offers CMC development and process optimization.

For peptide and oligonucleotide programs, a CDMO partner typically provides:

• Development of regulatory-ready CMC packages for IND, NDA, and BLA filings
• Scale-up from discovery batches to multi-kilogram GMP campaigns
• Analytical method development and comprehensive QA and QC oversight
• Late-phase and commercial manufacturing under global GMP standards

The value of a CDMO extends beyond outsourcing. The right partner helps pharmaceutical companies:

CPC Scientific delivers more than the traditional CDMO model. As a global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in peptides and oligonucleotides, we provide full-cycle services from discovery through commercial-scale production.

At CPC Scientific, we’ve adopted a “going with the compound” strategy, scaling our production capacity in line with confirmed customer demand and the broader development trends of the peptide industry. This ensures we stay agile, efficient, and closely aligned with our partners’ pipelines.

Based on market research, many API pipelines are expected to advance into commercial production over the next few years, driven by:

• Anticipated commercialization of pipeline projects already in development
• Strong market demand for peptide drug products, especially GLP-1 therapies
• Growing prevalence of generic peptide drugs

• • e.g. Tirzepatide, with patent expirations expected in 2036 (U.S.), 2037 (Europe), and 2040 (Japan)

Combined with our global GMP manufacturing expansions in both the United States and China, this puts CPC Scientific in an ideal position to capture upcoming opportunities and fully support our clients, as their programs move from discovery through commercial scale.

The global peptide and oligonucleotide markets are expanding rapidly, driven by the rise of GLP-1 therapies and new therapeutic modalities. To meet this growing demand, CPC Scientific is investing in capacity expansion, advanced automation, and global infrastructure.

A cornerstone of this effort is our new Rocklin, California facility, opening in 2026, which will significantly strengthen our late-phase and commercial-scale manufacturing capabilities.

Partnering with a CDMO is more than a transactional relationship, it’s a strategic decision that shapes the trajectory of your program. With our full-cycle capabilities, proven quality record, and global leadership, CPC Scientific is uniquely positioned to help advance peptide and oligonucleotide pipelines end-to-end, from discovery to commercialization.

Ready to accelerate your next milestone? Contact our team today to explore how CPC Scientific can move your peptide and oligo programs forward.